Evidence map›Paper›PMID 34984103›Full record

ArticleMolecular and clinical oncology2022

Overexpression of the PPAR-γ protein in primary Ta/T1 non-muscle-invasive urothelial carcinoma.

Shinichi Tanaka, Yasunori Tokuhara, Sho Hosokawa, Hiroyuki Ohsaki, Tatsuya Morinishi, Tamami Yamamoto, Norihiro Teramoto, Eiichiro Hirakawa

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Shinichi TanakaLaboratory of Pathology, Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Kagawa 761-0123, Japan.
Yasunori TokuharaLaboratory of Pathology, Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Kagawa 761-0123, Japan.
Sho HosokawaDepartment of Medical Technology, Ehime Prefectural University of Health Sciences, Iyo, Ehime 791-2101, Japan.
Hiroyuki OhsakiLaboratory of Pathology, Department of Medical Technology, Kobe University Graduate School of Health Sciences, Kobe, Hyogo 654-0142, Japan.
Tatsuya MorinishiLaboratory of Pathology, Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Kagawa 761-0123, Japan.
Tamami YamamotoDepartment of Clinical Laboratory, Shikoku Cancer Center, Matsuyama, Ehime 791-0280, Japan.
Norihiro TeramotoDepartment of Clinical Laboratory, Shikoku Cancer Center, Matsuyama, Ehime 791-0280, Japan.
Eiichiro HirakawaLaboratory of Pathology, Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Takamatsu, Kagawa 761-0123, Japan.
Kagawa Prefectural College of Health Sciences · JPShikoku Cancer Center · JPEhime Prefectural University of Health Science · JPHyogo University of Health Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a well-known nuclear receptor that is activated in the nucleus to regulate several transcription factors. Its expression patterns have been examined in various types of cancer. The present study investigated the expression patterns of PPAR-γ in non-muscle-invasive urothelial carcinoma. The expression rates of PPAR-γ, p53 and Ki-67 were compared to determine whether PPAR-γ may be considered as an immunobiomarker for bladder cancer. The intensity and extent of PPAR-γ expression were evaluated in 79 cases of non-muscle-invasive urothelial carcinoma (30 cases of papillary carcinoma low-grade, 30 cases of high-grade and 19 cases of carcinoma

Indexed as

immunohistochemical stainingnon-muscle-invasive urothelial carcinomaperoxisome proliferator-activated receptor-γ

Identifiers

PMID34984103
PMCPMC8719252
OpenAlexW4200474610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.